[HTML][HTML] High-throughput prioritization of target proteins for development of new antileishmanial compounds
Leishmaniasis, a vector-borne disease, is caused by the infection of Leishmania spp.,
obligate intracellular protozoan parasites. Presently, human vaccines are unavailable, and …
obligate intracellular protozoan parasites. Presently, human vaccines are unavailable, and …
An insight into differential protein abundance throughout Leishmania donovani promastigote growth and differentiation
PJ Alcolea, A Alonso, F García-Tabares… - International …, 2023 - Springer
Leishmania donovani causes anthroponotic visceral leishmaniasis, responsible for about
50,000 annual deaths worldwide. Current therapies have considerable side effects. Drug …
50,000 annual deaths worldwide. Current therapies have considerable side effects. Drug …
Drug discovery and development for kinetoplastid diseases
CR Caffrey, D Steverding, RS Ferreira… - … Chemistry and Drug …, 2003 - Wiley Online Library
In this article, we review the disease, biology, and biochemistry of kinetoplastids, as well as
the new drugs and drug candidates that have entered the clinic in the last decade. We also …
the new drugs and drug candidates that have entered the clinic in the last decade. We also …
Biorreator da 5'-deoxi-5'-metiltioadenosina fosforilase: do desenvolvimento a aplicação em ensaios de afinidade
JG Rodrigues - 2023 - repositorio.ufscar.br
Enzimas são biocatalisadores com alta especificidade e seletividade e mediam o
metabolismo fisiológico em uma variedade de processos nos organismos vivos, sendo …
metabolismo fisiológico em uma variedade de processos nos organismos vivos, sendo …